[3H]imipramine binding in idiopathic pain syndromes. Basal values and changes after treatment with antidepressants.
The binding affinity (Bmax, Kd) of [3H]imipramine to platelet membranes was investigated in 43 patients with a diagnosis of idiopathic pain syndrome. Measurements were carried out prior to and after 6 weeks' treatment with the antidepressants clomipramine or maprotiline (randomized double-blind trial). Before treatment the Bmax was 11% lower (1109 +/- 237 fmol/mg protein) compared to historical control subjects (n = 21, 1240 +/- 390) and comparable to patients with psychogenic pain with affective symptoms (n = 62, 1110 +/- 360) previously measured at the same laboratory. The Kd was 0.5 +/- 0.3 nM comparable to the Kd of the controls (0.6 +/- 0.2). After 6 weeks of treatment the clomipramine group (n = 11) had significantly lower Bmax = 208.5 +/- 286 (P less than 0.001). In the maprotiline-treated patients (n = 18) the Bmax values (1221 +/- 258) tended to increase towards the values of the controls but without statistical significance. No significant statistical correlation was found between initial Bmax values and clinical outcome.
Eberhard
G
G
Dept. of Psychiatry, Malmö General Hospital, S-214 01 MalmöSweden Dept. of Psychiatry, Umeå University, S-901 85 UmeåSweden Psychochemistry Institute, University of Copenhagen, DK-2100 CopenhagenDenmark Ciba-Geigy Company, Med. Dept., S-421 26 Västra FrölundaSweden Dept. of Anesthesiology, Central Hospital, S-651 85 KarlstadSweden.
Von Knorring
L
L
Mellerup
E T
ET
Nilsson
H L
HL
Plenge
P
P
Sundequist
U
U
D000928:Antidepressive Agents / Q000627:therapeutic use; D001792:Blood Platelets / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D004311:Double-Blind Method; D006801:Humans; D007099:Imipramine / Q000378:metabolism*; D066298:In Vitro Techniques; D010146:Pain / Q000503:physiopathology*; D059408:Pain Management
D000928:Antidepressive Agents; D007099:Imipramine